VERTEX PHARMACEUTICALS (EUROPE) LIMITED

• ◆

  1 PSC ceased in last 24 months

  Significant control changed hands — see the Ownership section.

1. VERTEX PHARMACEUTICALS (EUROPE) LIMITED 1994-08-12 → present
2. INTERCEDE 1083 LIMITED 1994-03-11 → 1994-08-12

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

BDO LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“For the year ended 31 December 2024, the Company had net assets of $4,295 million (2023: $3,729 million) and generated a profit after tax of $1,072 million (2023: $716 million). Vertex Pharmaceuticals Inc., has confirmed in writing that it will support the Company to continue trading and enable it to meet its liabilities as they fall due for at least 12 months from the approval of these financial statements. The directors have considered the financial and operating ability of the Group headed by Vertex Pharmaceuticals Inc. and are confident that the Group has sufficient liquidity to provide on-going financial support. The directors continue to monitor macroeconomic events and have determined that the Company is well prepared from a business continuity perspective. Accordingly, the directors continue to adopt a going concern basis in preparing the financial statements.”

Group structure

1. VERTEX PHARMACEUTICALS (EUROPE) LIMITED · parent
   1. Vertex Pharmaceuticals (Ireland) Limited 100% · Republic of Ireland · Distributor of small molecular medicine
   2. Vertex Pharmaceuticals (Sweden) AB 100% · Sweden · Sales and marketing of medical products
   3. Vertex Pharmaceuticals (CH) GmbH 100% · Switzerland · Distributor of small molecular medicine
   4. Vertex Pharmaceuticals (Portugal) Unipessoal Lda 100% · Portugal · Distributor of small molecular medicine
   5. Vertex Pharmaceuticals GmbH 100% · Austria · Distributor of small molecular medicine
   6. Vertex Pharmaceuticals (U.K.) Limited 100% · UK · Non trading
   7. Vertex Pharmaceuticals Single Member Societe Anonyme 100% · Greece · Distributor of small molecular medicine
   8. Vertex Pharmaceuticals (Poland) sp. z o.o 100% · Poland · Sales and marketing of medical products
   9. Vertex Pharmaceuticals (Czech Republic) s.r.o 100% · Czech Republic · Sales and marketing of medical products
   10. Vertex Pharmaceuticals (Belgium) B.V. 100% · Belgium · Distributor of small molecular medicine
   11. Vertex Farmacêutica do Brasil Ltda 100% · Brazil · Sales and marketing of medical products
   12. Vertex Pharmaceuticals Limited d.o.o Beograd 100% · Serbia · Sales and marketing of medical products
   13. Company for Services and Trade Vertex Pharmaceuticals Dooel Skopje 100% · North Macedonia · Sales and marketing of medical products
   14. Vertex Pharmaceuticals (Chile) SpA 100% · Chile · Sales and marketing of medical products

Significant events

• “Subsequent to the year end the directors recommended the payment of interim dividends in respect of the year ending 31 December 2025 of $200 million. This recommendation was approved during the shareholders meeting on 11 June 2025.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

6

last 12 months

Capital events

0

last 24 months

Officers appointed

3

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +30.6%

  £7,183,423,277 → £9,384,722,016

• Cash

  +51.7%

  £347,455,152 → £527,204,596

• Net assets

  +15.2%

  £2,764,553,002 → £3,183,872,498

• Employees

  +10.7%

  643 → 712

• Operating profit

  +44.4%

  £732,346,182 → £1,057,746,479

• Profit before tax

  +35.4%

  £768,673,091 → £1,040,516,679

• Wages

  +21.7%

  £67,227,576 → £81,829,503

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers